Devon L Graham
Overview
Explore the profile of Devon L Graham including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
696
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lee G, Graham D, Noble B, Trammell T, McCarthy D, Anderson L, et al.
Front Behav Neurosci
. 2022 Jan;
15:815713.
PMID: 35095443
Developmental dysregulation of dopamine D2 receptors (D2Rs) alters neuronal migration, differentiation, and behavior and contributes to the psychopathology of neurological and psychiatric disorders. The current study is aimed at identifying...
2.
Graham D, Madkour H, Noble B, Schatschneider C, Stanwood G
Neurotoxicol Teratol
. 2021 Apr;
87:106984.
PMID: 33864929
Evidence supporting the use of glucagon-like peptide-1 (GLP-1) analogues to pharmacologically treat disorders beyond type 2 diabetes and obesity is increasing. However, little is known about how activation of the...
3.
Trammell T, Henderson N, Madkour H, Stanwood G, Graham D
Neurol Sci
. 2020 Nov;
42(7):2911-2919.
PMID: 33222103
Rationale: The activation of the glucagon-like peptide-1 receptor (GLP-1R) has been purported to have antidepressant-like and cognitive-enhancing effects. Many people suffering from major depressive disorder (MDD) also experience deficits in...
4.
Graham D, Durai H, Trammell T, Noble B, Mortlock D, Galli A, et al.
J Comp Neurol
. 2020 Mar;
528(14):2445-2470.
PMID: 32170734
Glucagon-like peptide-1 (GLP-1) is an incretin hormone with a number of functions to maintain energy homeostasis and contribute to motivated behavior, both peripherally and within the central nervous system (CNS)....
5.
Goldfarb S, Stanwood G, Flynn H, Graham D
Exp Biol Med (Maywood)
. 2019 Oct;
245(2):131-137.
PMID: 31630569
No abstract available.
6.
Larson J, Graham D, Singer L, Beckwith A, Terplan M, Davis J, et al.
Pediatrics
. 2019 Jul;
144(2).
PMID: 31320466
The developmental impact of opioid use during pregnancy is a subject of ongoing debate. Short-term neonatal outcomes, such as lower birth weight and neonatal abstinence syndrome, are the most well-recognized...
7.
Jablonski S, Graham D, Vorhees C, Williams M
Neurotox Res
. 2016 Nov;
31(2):269-282.
PMID: 27817108
Neonatal exposure to methamphetamine (MA) and developmental chronic stress significantly alter neurodevelopmental profiles that show a variety of long-term physiological and behavioral effects. In the current experiment, Sprague-Dawley rats were...
8.
Martin M, Graham D, McCarthy D, Bhide P, Stanwood G
Birth Defects Res C Embryo Today
. 2016 Jun;
108(2):147-73.
PMID: 27345015
Exposure to drugs early in life has complex and long-lasting implications for brain structure and function. This review summarizes work to date on the immediate and long-term effects of prenatal...
9.
Amos-Kroohs R, Graham D, Grace C, Braun A, Schaefer T, Skelton M, et al.
Neurotoxicology
. 2016 Mar;
54:22-33.
PMID: 26943976
The level of lead (Pb) exposure in children has decreased dramatically since restrictions on its use were implemented. However, even with restrictions, children are exposed to Pb and still present...
10.
Sorensen G, Reddy I, Weikop P, Graham D, Stanwood G, Wortwein G, et al.
Physiol Behav
. 2015 Jun;
149:262-8.
PMID: 26072178
Glucagon-like peptide 1 (GLP-1) analogues are used for the treatment of type 2 diabetes. The ability of the GLP-1 system to decrease food intake in rodents has been well described...